Newly-established Swiss biotech MoonLake Immunotherapeutics has in-licensed the tri-specific nanobody sonelokimab (M1095/ALX 0761) from Germany’s Merck KGaA (MRK: DE).
MoonLake has been set up by an international team of immunology specialists to leverage revolutionary nanobody (single-domain antibody) technology in multiple indications. It will accelerate the clinical development of sonelokimab, building on robust clinical data generated by Merck and by Ablynx, a Sanofi (Euronext: SAN) company, which discovered the molecule. No financial terms of the accord are disclosed.
Sonelokimab has clinically demonstrated potential to drive disease modification in dermatology and rheumatology patients. Sonelokimab is a tri-specific, balanced interleukin (IL)-17A/F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze